MaxCyte Appoints Ali
Soleymannezhad as Chief Commercial Officer
Rockville, MD, Oct. 10, 2024 -
MaxCyte, Inc., (Nasdaq: MXCT; LSE:
MXCT), a leading, cell-engineering focused
company providing enabling platform technologies to advance the
discovery, development and commercialization of next-generation
cell-based therapeutics and innovative bioprocessing
applications, today
announced the appointment of Ali Soleymannezhad as Chief Commercial
Officer, effective as of September 11, 2024.
In his new role, Mr. Soleymannezhad
will lead MaxCyte's commercial operations to increase adoption of
the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to
customers, and expand the Company's market
impact in Cell and Gene Therapy. Prior to his role as Chief
Commercial Officer, Mr. Soleymannezhad was the Executive Vice
President of Bioprocessing, where he led global product development
and marketing strategy for MaxCyte's bioprocessing
business.
"I am delighted to promote Ali to the
role of Chief Commercial Officer," said Maher Masoud, President and
CEO of MaxCyte. "His diverse experience, skills, and leadership at
MaxCyte as Executive Vice President of Bioprocessing have
strengthened our organization's product development and commercial
strategies. We look forward to working alongside Ali as he leads
our commercial efforts to drive future growth at
MaxCyte."
Mr. Soleymannezhad brings 20 years of
technical sales, marketing, and product development experience to
his new role. Prior to Executive Vice President of Bioprocessing at
MaxCyte, he served as Executive Vice President for the Separations
and Purification business at Tosoh Bioscience and oversaw a team of
140 employees across four global manufacturing, development, and
commercial sites. Mr. Soleymannezhad was also Vice President of
Global Marketing and Business Development and Director of Sales and
Marketing-Americas at Tosoh and served on the board of Semba
Biosciences.
"I am excited to apply my experience
in sales and marketing and global business strategy to MaxCyte's
commercial efforts," said Ali Soleymannezhad, CCO of MaxCyte. "I
look forward to working with our executive team to continue
MaxCyte's commitment to supporting our customer's Cell and Gene
therapy work in research, through the clinic, and
beyond."
About MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation® technology, has been designed to support
the rapidly expanding cell therapy market and can be utilized
across the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology platform, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at
maxcyte.com and follow us on
X and
LinkedIn.
Forward-Looking Statements
This press release contains
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. These statements about us and our industry involve
substantial known and unknown risks, uncertainties, and assumptions
that may cause our actual results, performance or achievements to
be materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. All statements other than statements of historical
facts contained in this press release, including statements
regarding our future results of operations or financial condition,
business strategy and plans and objectives of management for future
operations, are forward-looking statements. Forward-looking
statements include, but are not limited to, statements about the
Company's projected full-year total revenue, core revenue, and SPL
program revenue and statements about possible or future results of
operations or financial position. In some cases, you can identify
forward-looking statements because they contain words such as
"may," "might," "will," "could," "would," "should," "expect,"
"plan," "anticipate," "intend," "believe," "expect," "estimate,"
"seek," "predict," "future," "project," "potential," "continue,"
"contemplate," "target," the negative of these words and similar
words or expressions. These statements are inherently uncertain,
and investors are cautioned not to unduly rely on these statements.
The forward-looking statements contained in this press release,
include, without limitation, statements concerning the following:
our expected future growth and success of our business model; the
size and growth potential of the markets for our products, and our
ability to serve those markets, increase our market share, and
achieve and maintain industry leadership; and our ability to expand
our customer base and enter into additional SPL
partnerships.
These and other risks and
uncertainties are described in greater detail in Item 1A , entitled
"Risk Factors," in our Annual Report on Form 10-K for the year
ended December 31, 2023, filed with the Securities and Exchange
Commission on or about March 12, 2024, as well as in discussions of
potential risks, uncertainties, and other important factors in the
other filings that we make with the Securities and Exchange
Commission from time to time. These documents are available through
the Investor Menu, Financials section, under "SEC Filings" on the
Investors page of our website at http://investors.maxcyte.com. Any
forward-looking statements in this press release are based on our
current beliefs and opinions on the relevant subject based on
information available to us as of the date of such press release,
and you should not rely on forward-looking statements as
predictions of future events. We undertake no obligation to update
any forward-looking statements made in this press release to
reflect events or circumstances after the date of this press
release or to reflect new information or the occurrence of
unanticipated events, except as required by law.
MaxCyte Contacts:
US IR
Adviser
Gilmartin
Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media
Relations
Spectrum
Science
Jordan Vines
jvines@spectrumscience.com
+1 540-629-3137
Nominated Adviser and Joint
Corporate Broker
Panmure Liberum
Emma Earl / Freddy
Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR
Adviser
ICR
Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com